Freshfields LLP has advised argenx. Wilson Sonsini Goodrich & Rosati, P.C. has advised Forte Biosciences. Argen NV ADR (NASDAQ: ARGX) and Forte Biosciences, Inc. (NASDAQ: FBRX)...
argenx Acquires Forte Biosciences for $2.2 Billion, Adding First-in-Class Anti-CD122 Antibody to Immunology Pipeline
Legend Biotech Announces $226 Million Public Offering of ADSs
Wilson Sonsini Goodrich & Rosati, Professional Corporation has advised the underwriters with respect to U.S. federal securities law and New York State law. Cooley LLP has...
Forte Biosciences Announces $150 Million Public Offering of Common Stock
Wilson Sonsini Goodrich & Rosati has advised Forte Biosciences. Paul Hastings LLP has advised Guggenheim Securities and Barclays. Forte Biosciences, Inc., a clinical-stage biopharmaceutical company specializing...
Novartis Acquires Avidity Biosciences in USD 12 Billion Transaction and Completes USD 11 Billion Financing
Covington and Homburger have advised Novartis. Kirkland & Ellis and Wilson Sonsini Goodrich & Rosati have advised Avidity Biosciences. Linklaters has advised a global underwriting syndicate....
Avidity Biosciences Prices $600 Million Upsized Public Offering of Common Stock
Wilson Sonsini Goodrich & Rosati along with Latham & Walkins have advised Avidity Biosciences. Avidity Biosciences, Inc., a biopharmaceutical company listed on Nasdaq under the symbol...
Forte Biosciences Announces $75 Million Public Offering of Common Stock and Pre-Funded Warrants
Wilson Sonsini Goodrich & Rosati has advised Forte Biosciences, Inc. on the offering, and Paul Hastings has advised the underwriters. Forte Biosciences, Inc., a clinical-stage biopharmaceutical...
CRISPR Therapeutics’ Multi-Target Collaboration with Sirius Therapeutics
Wilson Sonsini Goodrich & Rosati advised Sirius on patent matters related to the transaction. CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based...
Sirius Therapeutics’ $50 Million Series B2 Financing Round
Wilson Sonsini Goodrich & Rosati advised Sirius Therapeutics on patent matters related to the transaction. Biotechnology company Sirius Therapeutics (Sirius) announced that it has completed nearly...
Oak Hill Bio’s License Agreement with Roche
Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on patent matters related to the transaction. Oak Hill Bio, a biotechnology company focused on acquiring and...
Verdiva Bio’s $410 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised General Atlantic on IP matters related to the transaction. Verdiva Bio Limited announced its launch as a clinical-stage biopharmaceutical company...
Forte Biosciences’ $53 Million Equity Financing
Wilson Sonsini Goodrich & Rosati represented Forte Biosciences, while Paul Hastings advised TD Cowen in the transaction. Biopharmaceutical company, Forte Biosciences, announced an oversubscribed $53 million...
Seaport Therapeutics’ $225 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised General Atlantic on patent matters related to the transaction. Seaport Therapeutics (Seaport), a clinical-stage biopharmaceutical company that is advancing novel...